Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Cognitive behavioral therapy and self-help may improve unexplained symptoms of pain, fatigue

A new type of therapy may help people with symptoms such as pain, weakness, or dizziness that can't be explained by an underlying disease, according to a study published in the July 27, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Jul 2011

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

28 Jul 2011

New enhanced MS ActiveSource for patients with multiple sclerosis

Biogen Idec today announced it has strengthened MS ActiveSource, its industry-leading suite of services for people with multiple sclerosis (MS), with the addition of new resources and support programs.

28 Jul 2011

Teva second quarter net sales increase 11% to $4.2 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2011.

27 Jul 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Myelin regulates key protein involved in sending long-distance signals

The development of a new cell-culture system that mimics how specific nerve cell fibers in the brain become coated with protective myelin opens up new avenues of research about multiple sclerosis. Initial findings suggest that myelin regulates a key protein involved in sending long-distance signals.

22 Jul 2011

Longer looks: The effect of bedside manner; digging deep on Rick Scott's business deals; migraines and sexism

Even if your doctor doesn't have the best beside manner, you're probably willing to excuse her behavior as long as she treats your condition and makes you healthy again, right? Well, you might not want to be so forgiving. It turns out that rudeness and incivility among doctors, in particular in the operating room, can actually lead to poorer health outcomes and even higher death rates among patients.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

High cost of multiple sclerosis drugs

According to a study released this Wednesday, drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost.

21 Jul 2011

Medco enters definitive merger agreement with Express Scripts

Express Scripts, Inc. and Medco Health Solutions, Inc. today announced that they have entered into a definitive merger agreement.

21 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Dealing with chronic pain

For people with severe chronic pain like Kelly Young and Teresa Shaffer—both of whom have become patient advocates —coping with agony is a fact of life. Young suffers from rheumatoid arthritis while Shaffer's pain is linked primarily to another degenerative bone disease.

21 Jul 2011

Study examines cost-effectiveness of MS drugs in the U.S.

A new study examining the cost-effectiveness of drugs to treat multiple sclerosis (MS) in the United States finds that the health gains from these drugs come at a very high cost compared to basic therapy to control the symptoms of MS and compared to treatments for other chronic diseases.

21 Jul 2011

Intense visual stimulation renders nerve cells more receptive to subsequent learning

Dr. Ed Ruthazer is a mapmaker but, his landscape is the developing brain - specifically the neuronal circuitry, which is the network of connections between nerve cells. His research at The Montreal Neurological Institute and Hospital - The Neuro at McGill University, reveals the brain as a dynamic landscape where connections between nerves are plastic, changing and adapting to the demands of the environment.

21 Jul 2011

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

In a study published recently in the journal Science Signaling Van Andel Research Institute (VARI) scientists demonstrate on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating inflammation and a multitude of autoimmune diseases such as arthritis, multiple sclerosis, and certain cancers.

19 Jul 2011

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.

18 Jul 2011

IHD blood test for Alzheimer's disease yields 83% sensitivity and 82% specificity

Innovative Health Diagnostics (IHD), the innovative company specialising in the development of diagnostic blood tests for Alzheimer's disease and neurodegenerative illnesses presents its first clinical results for its IHD-Amy blood test for Alzheimer's disease.

18 Jul 2011

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Cognitive behavioral therapy and self-help may improve unexplained symptoms of pain, fatigue

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

New enhanced MS ActiveSource for patients with multiple sclerosis

Teva second quarter net sales increase 11% to $4.2 billion

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Myelin regulates key protein involved in sending long-distance signals

Longer looks: The effect of bedside manner; digging deep on Rick Scott's business deals; migraines and sexism

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

High cost of multiple sclerosis drugs

Medco enters definitive merger agreement with Express Scripts

Public disclosure of Bachmann's migraine condition raises much-needed awareness

Dealing with chronic pain

Study examines cost-effectiveness of MS drugs in the U.S.

Intense visual stimulation renders nerve cells more receptive to subsequent learning

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

IHD blood test for Alzheimer's disease yields 83% sensitivity and 82% specificity

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in